Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015

B. L. Bermas, S. C. Kim, K. Huybrechts, H. Mogun, S. Hernandez-Diaz, B. T. Bateman, R. J. Desai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Evidence suggests that continuing hydroxychloroquine (HCQ) during pregnancy in women with systemic lupus erythematosus (SLE) improves outcomes. We sought to describe time trends in the continuation, initiation, and duration of HCQ in a large population-based cohort of pregnant SLE women. Methods: A cohort of pregnant women with SLE enrolled continuously in public (Medicaid, 2001–2010) or private (Optum Clinformatics, 2003–2015) health insurance between three months prior to conception and one month after delivery was identified. We assessed the proportion of women initiating or continuing HCQ and the duration of therapy during each calendar year in the study. Results: A total of 5300 women with SLE were included. Of these, 852 (16.1%) were on HCQ treatment in the three-month period prior to their pregnancy. During pregnancy, the overall proportion of women with SLE taking HCQ increased from 12.4% in 2001 to 37.7% in 2015. Initiation of HCQ therapy during pregnancy increased from 2.7% in 2001 to 7.5% in 2010 (p = 0.0002) (Medicaid) and from 4.9% in 2003 to 13.6% in 2015 (p = 0.0001) (Clinformatics). Continuation of HCQ during pregnancy did not change significantly over time in either data set. The average cumulative day-supply of HCQ prescriptions during pregnancy increased from 37 days in 2001 to 77 days in 2010 (p = 0.05) among HCQ initiators and from 79 days in 2001 to 125 days in 2010 (p = 0.0009) among HCQ continuers in Medicaid. Among privately insured women, the average cumulative day-supply of HCQ prescriptions among HCQ continuers increased from 84 in 2004 to 163 in 2015 (p = 0.0006) but did not change significantly among HCQ initiators. Conclusion: The proportion of women initiating HCQ during pregnancy and the average cumulative day-supply of HCQ increased from 2001 to 2015. While these findings are encouraging, overall HCQ use during pregnancy remains low.

Original languageEnglish (US)
Pages (from-to)1012-1017
Number of pages6
JournalLupus
Volume27
Issue number6
DOIs
StatePublished - May 1 2018

Fingerprint

Hydroxychloroquine
Systemic Lupus Erythematosus
Pregnancy
Medicaid
Prescriptions

Keywords

  • hydroxychloroquine
  • Pregnancy
  • SLE

ASJC Scopus subject areas

  • Rheumatology

Cite this

Bermas, B. L., Kim, S. C., Huybrechts, K., Mogun, H., Hernandez-Diaz, S., Bateman, B. T., & Desai, R. J. (2018). Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015. Lupus, 27(6), 1012-1017. https://doi.org/10.1177/0961203317749046

Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015. / Bermas, B. L.; Kim, S. C.; Huybrechts, K.; Mogun, H.; Hernandez-Diaz, S.; Bateman, B. T.; Desai, R. J.

In: Lupus, Vol. 27, No. 6, 01.05.2018, p. 1012-1017.

Research output: Contribution to journalArticle

Bermas, BL, Kim, SC, Huybrechts, K, Mogun, H, Hernandez-Diaz, S, Bateman, BT & Desai, RJ 2018, 'Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015', Lupus, vol. 27, no. 6, pp. 1012-1017. https://doi.org/10.1177/0961203317749046
Bermas, B. L. ; Kim, S. C. ; Huybrechts, K. ; Mogun, H. ; Hernandez-Diaz, S. ; Bateman, B. T. ; Desai, R. J. / Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015. In: Lupus. 2018 ; Vol. 27, No. 6. pp. 1012-1017.
@article{6f6f3c3f0b3a4dc3846ef81d22d60361,
title = "Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015",
abstract = "Background: Evidence suggests that continuing hydroxychloroquine (HCQ) during pregnancy in women with systemic lupus erythematosus (SLE) improves outcomes. We sought to describe time trends in the continuation, initiation, and duration of HCQ in a large population-based cohort of pregnant SLE women. Methods: A cohort of pregnant women with SLE enrolled continuously in public (Medicaid, 2001–2010) or private (Optum Clinformatics, 2003–2015) health insurance between three months prior to conception and one month after delivery was identified. We assessed the proportion of women initiating or continuing HCQ and the duration of therapy during each calendar year in the study. Results: A total of 5300 women with SLE were included. Of these, 852 (16.1{\%}) were on HCQ treatment in the three-month period prior to their pregnancy. During pregnancy, the overall proportion of women with SLE taking HCQ increased from 12.4{\%} in 2001 to 37.7{\%} in 2015. Initiation of HCQ therapy during pregnancy increased from 2.7{\%} in 2001 to 7.5{\%} in 2010 (p = 0.0002) (Medicaid) and from 4.9{\%} in 2003 to 13.6{\%} in 2015 (p = 0.0001) (Clinformatics). Continuation of HCQ during pregnancy did not change significantly over time in either data set. The average cumulative day-supply of HCQ prescriptions during pregnancy increased from 37 days in 2001 to 77 days in 2010 (p = 0.05) among HCQ initiators and from 79 days in 2001 to 125 days in 2010 (p = 0.0009) among HCQ continuers in Medicaid. Among privately insured women, the average cumulative day-supply of HCQ prescriptions among HCQ continuers increased from 84 in 2004 to 163 in 2015 (p = 0.0006) but did not change significantly among HCQ initiators. Conclusion: The proportion of women initiating HCQ during pregnancy and the average cumulative day-supply of HCQ increased from 2001 to 2015. While these findings are encouraging, overall HCQ use during pregnancy remains low.",
keywords = "hydroxychloroquine, Pregnancy, SLE",
author = "Bermas, {B. L.} and Kim, {S. C.} and K. Huybrechts and H. Mogun and S. Hernandez-Diaz and Bateman, {B. T.} and Desai, {R. J.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1177/0961203317749046",
language = "English (US)",
volume = "27",
pages = "1012--1017",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015

AU - Bermas, B. L.

AU - Kim, S. C.

AU - Huybrechts, K.

AU - Mogun, H.

AU - Hernandez-Diaz, S.

AU - Bateman, B. T.

AU - Desai, R. J.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: Evidence suggests that continuing hydroxychloroquine (HCQ) during pregnancy in women with systemic lupus erythematosus (SLE) improves outcomes. We sought to describe time trends in the continuation, initiation, and duration of HCQ in a large population-based cohort of pregnant SLE women. Methods: A cohort of pregnant women with SLE enrolled continuously in public (Medicaid, 2001–2010) or private (Optum Clinformatics, 2003–2015) health insurance between three months prior to conception and one month after delivery was identified. We assessed the proportion of women initiating or continuing HCQ and the duration of therapy during each calendar year in the study. Results: A total of 5300 women with SLE were included. Of these, 852 (16.1%) were on HCQ treatment in the three-month period prior to their pregnancy. During pregnancy, the overall proportion of women with SLE taking HCQ increased from 12.4% in 2001 to 37.7% in 2015. Initiation of HCQ therapy during pregnancy increased from 2.7% in 2001 to 7.5% in 2010 (p = 0.0002) (Medicaid) and from 4.9% in 2003 to 13.6% in 2015 (p = 0.0001) (Clinformatics). Continuation of HCQ during pregnancy did not change significantly over time in either data set. The average cumulative day-supply of HCQ prescriptions during pregnancy increased from 37 days in 2001 to 77 days in 2010 (p = 0.05) among HCQ initiators and from 79 days in 2001 to 125 days in 2010 (p = 0.0009) among HCQ continuers in Medicaid. Among privately insured women, the average cumulative day-supply of HCQ prescriptions among HCQ continuers increased from 84 in 2004 to 163 in 2015 (p = 0.0006) but did not change significantly among HCQ initiators. Conclusion: The proportion of women initiating HCQ during pregnancy and the average cumulative day-supply of HCQ increased from 2001 to 2015. While these findings are encouraging, overall HCQ use during pregnancy remains low.

AB - Background: Evidence suggests that continuing hydroxychloroquine (HCQ) during pregnancy in women with systemic lupus erythematosus (SLE) improves outcomes. We sought to describe time trends in the continuation, initiation, and duration of HCQ in a large population-based cohort of pregnant SLE women. Methods: A cohort of pregnant women with SLE enrolled continuously in public (Medicaid, 2001–2010) or private (Optum Clinformatics, 2003–2015) health insurance between three months prior to conception and one month after delivery was identified. We assessed the proportion of women initiating or continuing HCQ and the duration of therapy during each calendar year in the study. Results: A total of 5300 women with SLE were included. Of these, 852 (16.1%) were on HCQ treatment in the three-month period prior to their pregnancy. During pregnancy, the overall proportion of women with SLE taking HCQ increased from 12.4% in 2001 to 37.7% in 2015. Initiation of HCQ therapy during pregnancy increased from 2.7% in 2001 to 7.5% in 2010 (p = 0.0002) (Medicaid) and from 4.9% in 2003 to 13.6% in 2015 (p = 0.0001) (Clinformatics). Continuation of HCQ during pregnancy did not change significantly over time in either data set. The average cumulative day-supply of HCQ prescriptions during pregnancy increased from 37 days in 2001 to 77 days in 2010 (p = 0.05) among HCQ initiators and from 79 days in 2001 to 125 days in 2010 (p = 0.0009) among HCQ continuers in Medicaid. Among privately insured women, the average cumulative day-supply of HCQ prescriptions among HCQ continuers increased from 84 in 2004 to 163 in 2015 (p = 0.0006) but did not change significantly among HCQ initiators. Conclusion: The proportion of women initiating HCQ during pregnancy and the average cumulative day-supply of HCQ increased from 2001 to 2015. While these findings are encouraging, overall HCQ use during pregnancy remains low.

KW - hydroxychloroquine

KW - Pregnancy

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=85046797846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046797846&partnerID=8YFLogxK

U2 - 10.1177/0961203317749046

DO - 10.1177/0961203317749046

M3 - Article

C2 - 29301469

AN - SCOPUS:85046797846

VL - 27

SP - 1012

EP - 1017

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 6

ER -